Question · Q4 2025
Ronnie Kim inquired about any additional patents or layers of protection Ardelyx is building for tenapanor, and how the company views long-term XPHOZAH growth post-2026, considering potential adjustments in Medicare base rates for phosphate binders.
Answer
CEO Mike Raab confirmed ongoing efforts to strengthen intellectual property, highlighting the new formulation patent (Orange Book listed, expiring 2042) as a key component. He clarified that Medicare base rate adjustments are not relevant to XPHOZAH's revenue, as Ardelyx chose not to participate in that segment, focusing instead on Medicaid and commercial patients.
Ask follow-up questions
Fintool can predict 
ARDX's earnings beat/miss a week before the call